tradingkey.logo

Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence

ReutersJun 26, 2025 11:03 AM

- Revive Therapeutics Ltd RVV.CD:

  • REVIVE THERAPEUTICS NEARS COMPLETION OF KEY NERVE AGENT COUNTERMEASURE STUDY WITH CANADIAN DEPARTMENT OF NATIONAL DEFENCE HIGHLIGHTING SIGNIFICANT STOCKPILING OPPORTUNITY

  • REVIVE THERAPEUTICS LTD - BUCILLAMINE STUDY TO CONCLUDE BY SEPTEMBER 2025

  • REVIVE THERAPEUTICS LTD - PLANS TO EXPLORE BUCILLAMINE FOR TBI AND VIRAL INFECTIONS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI